Search details
1.
Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.
Ann Oncol
; 35(2): 190-199, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37872020
Results
1 -
1
de 1
1
Next >
>>